Supplements and Featured Publications
2021 Year in Review: Updates in Biomarker-Driven Lung Cancer
Volume: 1
Issue: 1
The 2021 Year in Review: Updates in Biomarker-Driven Lung Cancer is the digital version of a print publication encompasses some of the biggest data that have read out in bimarker-driven lung cancer in 2021, along with expert insights in article and video format.
Funding From Daiichi Sankyo/Content Developed Independently by OncLive
My Treatment Approach: Lung Cancer Practice Patterns
Volume: 1
Issue: 1
The Evolving Role of Immunotherapy in Metastatic Non–Small Cell Lung Cancer
Volume: 1
Issue: 1
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5